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Background: Cetuximab is a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR).
Skin reactions are the most common side effects of cetuximab. Rhagades of the tips of the fingers and toes, the
heels and especially the interphalangeal joints are one of the most frightening and painful dermatological side
effects that may develop from EGFR-inhibitor therapy. Rhagades are characterized by pain, severe tenderness and
poor healing response. They are challenging to treat. Thus, rhagades often poses the most significant threat to the
quality of life (QoL) for these patients. Ethyl-2-cyanoacrylate (ECA), an ethyl ester of the 2-cyano-2-propenoic acid,
is often used as adhesive in a variety of different work settings in industry, i.e. as a component in nail-care products
such as nail glue. In addition, ECA is used for various medical indications, such as for liquid bandages and for suture-less
surgery. Wound healing can be accelerated with ECA. The purpose of the SUPPORT trial is to investigate the efficacy of
ECA for the treatment of cetuximab-induced rhagades and to assess the clinical usefulness of the SUPO score, a new
classification system for rhagades induced by EGFR-inhibitor therapy.
Methods/Design: The SUPPORT trial is an open-label, prospective, randomized, national multicenter intervention study
to evaluate the effectiveness of ECA versus the standard treatment of each institution on the pain intensity and QoL
in patients with locally advanced head and neck cancer suffering from painful cetuximab-induced rhagades during
radioimmunotherapy. Primary endpoint is the assessment of the pain intensity 24 hours after application of ECA or
the standard treatment quantified by the visual analogue scale (VAS). Secondary endpoints are the evaluation of QoL
assessed by the EORTC-QoL-C30 questionnaire and the Dermatological Life Quality Index (DLQI).
Discussion: During treatment with EGFR inhibitors it is necessary to recognize and manage side effects promptly to
assure better patient QoL. The SUPPORT trial is the first randomized clinical trial evaluating a new treatment option for
painful cetuximab-induced rhagades. Furthermore, the new SUPO score will be prospectively assessed in terms of
clinical usefulness for classification of EGFR inhibitor-induced rhagades.
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Cetuximab is a chimeric monoclonal antibody against the
epidermal growth factor receptor (EGFR). It has shown
clinical activity against a variety of malignancies [1-5]. In
head and neck cancer cetuximab is approved in combin-
ation with radiotherapy as a curative treatment option for
patients with locally advanced squamous cell carcinoma of
the head and neck (LASCCHN). In the pivotal phase III
trial published by Bonner et al., a radioimmunotherapy
with cetuximab resulted in a higher response rate, an im-
provement of the duration of locoregional control and an
increased rate of 5-year overall survival [6-9]. Cetuximab,
as with the entire class of anti-EGFR inhibitors is associ-
ated with a high prevalence of dermatological side effects
[10-15]. Commonly experienced dermatological side ef-
fects include acneiform rash, hair changes, enhancement
of radiation-induced dermatitis, pruritus, mucositis, xero-
sis cutis, rhagades and paronychia. While acneiform rash
is the most common side effect during the first weeks of
application of the monoclonal antibody cetuximab, xerosis
of the skin and xerosis-associated rhagades usually develop
after at least 5 to 6 weeks of treatment with an anti-EGFR
inhibitor such as cetuximab [15-17]. In the European litera-
ture fissures of the skin and skin cracking are termed rha-
gades [18]. Rhagades of the fingertips and toes, of the
palms or knuckles, the heels, the soles and especially of the
interphalangeal joints are one of the most frightening and
painful dermatological side effects that may develop as late
phase skin reactions from EGFR-inhibitor therapy [19].
Rhagades occur in about 15% to 25% of all patients treated
with an EGFR-inhibitor and are characterized by pain, se-
vere tenderness and poor healing tendency. They can be
very painful and, furthermore, may create a risk for local or
systemic infection [16,17]. All of those dermatological tox-
icities including cetuximab-induced rhagades have often led
to reduction or even cessation of an effective anticancer
therapy and they have been shown to decrease patients'
quality of life (QoL) significantly. Activities of daily living
(ADL) may be impaired due to skin reactions, especially
due to anti-EGFR induced painful rhagades. Whereas pre-
vention and treatment recommendations for cetuximab-
induced acneiform rash are well established today and have
been published from several research groups recently
[13-24], treatment recommendations for the treatment of
cetuximab-induced painful rhagades are only reported an-
ecdotally [15-18]. Lacouture et al. published general recom-
mendations for the prevention and treatment of rhagades
recently based on their own expert opinion. The individual
recommendations for prevention of rhagades include the
wearing of protective footwear or covering the fingertips to
avoid friction; for treatment the authors recommended the
topical application of thick moisturizer, zinc oxide creams,
propylene glycol 50% solution, salicylic acid 10% ointment,
steroid tapes and hydrocolloid dressings or liquid glues likecyanoacrylate preparations to keep the rhagades from
worsening [17]. Limited evidence also supports the use
of silver nitrate or potassium permanganate foams and
topical antibiotics [17]. Oral antibiotics, however, may
be necessary if infection of the rhagades occurs and
worsens despite topical treatment. Randomized clinical
trials assessing the prevention or treatment of EGFR-
induced rhagades, however, have not been performed
so far. No published data are available supporting pre-
vention or treatment recommendations for those rha-
gades. Thus, evidence-based treatment recommendations
for anti-EGFR induced painful rhagades do not exist. All
recommendations are based on individual observation,
case studies and expert opinion. Another problem is that
for those rhagades typically seen during and after anti-
EGFR treatment no suitable classification system or scor-
ing system is available. The NCI CTCAE criteria do not
comprise a useful scoring system for this type of side ef-
fects [25]. Thus, an appropriate scoring system is war-
ranted to classify the EGFR inhibitor induced rhagades
and to allow rational treatment decisions based on a stan-
dardized clinical scoring system.
Liquid glues such as ethyl-2-cyanoacrylate (ECA), an
ethyl ester of the 2-cyano-2-propenoic acid, are often used
as adhesive in a variety of different work settings in indus-
try, e.g. as a component in nail-care products such as nail
glue. Besides, ECA is commonly used for various medical
indications, especially for the treatment of wounds, e.g. for
liquid bandages in children and for suture-less surgery. It
is a colorless liquid with low viscosity at normal room
temperature and it polymerizes rapidly in the presence of
moisture. Wound healing can be accelerated with ECA
[12,17,26-28]. ECA is suitable for the treatment of rhagades
due to the direct proportional influence of the OH-group
concentration of ECA on the age hardening velocity which
occurs within a spit second [17]. Sealing the cracks with
ECA may also help to relieve pain [17,26-28]. Furthermore,
applying ECA leads to wound closure and to an effective
germ barrier which may lower the rate of secondary wound
infections [29]. Dermatological toxicities, especially rha-
gades induced by EGFR inhibitors, critically affect patients’
health-related quality of life and, as a consequence, the dose
intensity of EGFR inhibitors and, thus, the effectiveness
of antineoplastic regimens. There are several patients
known from observation who did not receive their
planned course of anticancer treatment due to severe
cutaneous side effects and who, therefore, had a poorer
outcome of their disease. Due to the missing data from
clinical trials on the prevention and the management
of EGFR-inhibitor induced rhagades, the crucial im-
pact of rhagades on the patient’s wellbeing and QoL and
the adherence to anticancer treatment, prospective, ran-
domized, controlled clinical trials are warranted to evaluate
treatment options for EGFR-inhibitor induced rhagades,
Table 1 SUPO Score for the classification of rhagades
Grade 1: Rhagades without clinical symptoms
Grade 2: Painful rhagades
Grade 2a: Moderate pain, no impairment of activity in
the daily routine (ADL)
Grade 2b: Severe pain and impairment of the activities
of daily living (ADL)
Grade 3: Painful, deep and spontaneously bleeding rhagades
Grade 4: Superinfection of the rhagades (detection of bacterial growth)
Grade 4a: Local infection
Grade 4b: Systemic infection
Grade 5: Death due to complications of the rhagades
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based prevention and treatment guidelines.
The SUPPORT trial is a prospective, open-label, ran-
domized, controlled intervention trial exploring the ef-
ficacy of ethyl-2-cyanoacrylate for the treatment of
painful cetuximab-induced rhagades compared to the
standard treatment of each institution. In addition, the
clinical usefulness of the SUPO score, a new classifica-
tion system for rhagades induced by EGFR-inhibitor
therapy, will be assessed and validated in a clearly de-
fined patient cohort.
Methods and design
Study objectives
The purpose of the SUPPORT trial is to evaluate the
effect of topical applied ECA compared to standard
treatment on the pain intensity and quality of life in
patients suffering from painful cetuximab-induced rha-
gades during cetuximab-based radioimmunotherapy
for LASCCHN. Focus of the analysis is to evaluate a
superiority of ECA compared to any standard treat-
ment used in the participating institutions concerning
pain relieve and improvement of QoL.
Primary objective
Primary endpoint is the assessment of the pain inten-
sity 24 hours after application of ECA or the standard
treatment of each institution quantified by the visual
analogue scale (VAS).
Secondary objectives
Secondary endpoints are the pain intensity assessed 5 to 7
days after application of ECA or the standard treatment of
each institution quantified by the VAS and the evaluation
of QoL assessed by the EORTC-QoL-C30 questionnaire
and the Dermatological Life Quality Index (DLQI) 5 to 7
days after application of ECA or the standard treatment of
each institution. Furthermore, a photo documentation of
the rhagades will be performed on baseline, 24 hours after
first application of ECA or standard treatment and 5 to 7
days later. Furthermore, the SUPO score will be used at
screening, baseline, 24 hours and 5 to 7 days after applica-
tion of the specific treatment for diagnostics as well as for
the assessment of clinical response. The SUPO score is
shown in Table 1.
Design/Randomization
SUPPORT is a randomized controlled intervention study,
in which approximately 40-50 patients will be randomized
1:1 to receive ECA or the standard treatment of the institu-
tion (Figure 1). Allocation of patients to either treatment
group is concealed by using a centralised randomisation
procedure with a computer generated list produced by an
independent research organisation, i.e. iOMEDICO AG,Freiburg, Germany. The participating study center will
complete the randomization form and fax the page to
iOMEDICO AG. An iOMEDICO-employee not involved
in the project management, monitoring or data manage-
ment of the study will assign the treatment arm according
to the randomization list and will forward this information
to the study center. The randomization list will be kept in
safe and confidential custody at iOMEDICO AG.
Setting
The SUPPORT trial will be performed as a multicenter
study according to the § 23b of the German Medicinal
Devices Act (MPG). The study setting is national, with
approximately 40 sites in Germany. The SUPPORT trial
is designed by the study initiators of the Department of
Radiation Oncology and the Department of Medical
Oncology at the National Center for Tumor Diseases of
the University of Heidelberg Medical Center. In view of
the multimodal nature of the trial, all investigators are
experienced oncologists in the fields of radiation oncol-
ogy and medical oncology.
Patient selection: inclusion and exclusion criteria
Patients with the diagnosis of LASCCHN and treated with
primary definitive cetuximab-based radioimmunotherapy
within the HICARE clinical trial protocol [30] will be evalu-
ated and screened for the participation in the SUPPORT
trial at the time when they develop cetuximab-induced rha-
gades. All patients fulfilling the inclusion and exclusion cri-
teria will be informed about the study.
Inclusion criteria
Patients meeting all of the following criteria will be
considered for admission to the trial:
– LASCCHN and participation in the HICARE-phase-
IV-trial
– Cetuximab-induced painful rhagades, i.e. SUPO
Score 2-3 (see Figure 1)
– Compliance to the photo documentation
Total 40-50 patients:
Screening: Screening of patients for eligibility. Informed 
consent. Collection of trial relevant data and patient history.
Day 2, i.e. 24 hours after application of study treatment: 
Clinical assessment, VAS, SUPO Score, photo 
documentation.
Day 1: Application of study treatment according 
to study protocol.
Baseline: Clinical assessment. Pain Assessment by VAS. 
SUPO Score. Evaluation of QoL by EORTC-QoL-C30 
questionnaire and DLQI. Photo documentation. 
5 – 7 days after application of study treatment: 
Clinical assessment, VAS, SUPO Score, photo 
documentation. Evaluation of QoL by EORTC-QoL-C30 
questionnaire and DLQI. 
End of Study
Randomization
Figure 1 Flow chart of the SUPPORT trial.
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individual consequences of the clinical trial
– Written informed consent
Exclusion criteria
Patients presenting with any of the following criteria will
not be included in the trial:
– Cetuximab-induced rhagades without any pain,
i.e. SUPO Score 1 (see Figure 1)
– Cetuximab-induced rhagades, SUPO
Score 4, i.e. superinfection of the rhagades
(see Figure 1)
– Patients not being enrolled in the HICARE trial
– Substance misuse, psychoactive substance abuse
or psychological/social conditions leading to a
decreased patients’ compliance with possible
bad influence to the results of the study– Known allergic reaction to ethyl-2-cyanoacrylate
(ECA)
Treatment schedule
After achievement of the written informed consent pa-
tients will be 1:1 randomized in the experimental arm or
the control arm. All patients will receive a specific treat-
ment for their painful rhagades. In the experimental arm
patients will be topically treated with the liquid glue
ethyl-2-cyanoacrylate (ECA) whereas in the control arm
patients will obtain the standard therapy of the institu-
tion. All patients will be assessed for pain, SUPO Score
and QoL after 5 to 7 days, respectively.In case of insuffi-
cient response and absent clinical benefit of standard
treatment of the institution in the control arm 5 to 7
days after begin of treatment a cross over to the experi-
mental group can be performed due to ethical reasons.
No statistical influence on any endpoint will be expected
due to the cross over design. End of study is 5 to 7 days
after first application of ECA or the standard treatment
of the institution. No further follow-up visits are sched-
uled within the trial. The last patient included into the
study will be followed for exactly 5 to 7 days after start
of treatment. This is considered the final study visit. The
overall duration of the trial is expected to be approxi-
mately 24 months. All participants have the right to
drop out the trial at any time.
Assessment of safety parameters
Safety and toxicity of the study treatment will be evalu-
ated by clinical examination. The International Common
Terminology Criteria for Adverse Events (CTCAE) ver-
sion 4.02 will be used for toxicity and adverse event
reporting. A copy or the CTCAE can be accessed from
the CTEP home page: http://ctep.cancer.gov/protocol-
Development/electronic_applications/ctc.htm.
Statistical methods
Study hypothesis
The study is designed to demonstrate a superiority of
ECA compared to standard treatment of each institution
for treatment of cetuximab-induced painful rhagades.
Statistical calculations for trial sample size
The primary endpoint of this trial is the change of pain
24 hours after therapy compared to pain before therapy,
and pain is measured using a visual analog scale (VAS).
Assuming a mean difference in pain reduction of 20%
and a standard deviation of 20%, 17 evaluable patients
per group are needed to detect this difference with a
power of 1-β = 80% and a level of significance α = 5%
when applying a t-test. It can be expected that the actual
power of the test is higher when applying an analysis of
covariance with pain (VAS) before therapy as a
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another 3 patients have to be randomized in each of the
two treatment groups to get a total of n = 20 patients
per group.
Statistical methods
The confirmatory analysis is performed on the basis of
an intention-to-treat (ITT) population and with respect
to ITT principles. Additional analysis will be conducted
on the per-protocol population.
Descriptive statistics for continuous parameters and
scores include the number of non-missing observations,
mean, standard deviation, median, minimum and max-
imum, performed for the treatment groups and overall.
The description of categorical variables (ordinal or nom-
inal) includes the number and percentage of patients be-
longing to the relevant categories in the trial population
as well as to each treatment group.
The primary efficacy endpoint is the difference of the
pain score assessed by VAS 24 h after begin of treat-
ment. The underlying two sided null-hypothesis is that
both interventions lead to similar means of the VAS pain
in both intervention groups 24 hours after therapy.
H0 : μ1–μ2 ¼ 0
The alternative hypothesis is that any intervention per-
forms better than the other:
HA : μ1–μ2≠ 0
A confirmatory intention to treat analysis (2-sided
test), including all patients as randomized, will be per-
formed on the mean differences in the VAS pain values
between the two treatment groups. Analysis of covari-
ance (ANCOVA) techniques will be used to detect pos-
sible treatment effects, with VAS pain score before
therapy as a continuous covariate.
All patients will be included for analysis for secondary
endpoints treated at least once with the study treatment.
Secondary endpoints will be analyzed in an exploratory
fashion, using appropriate statistical methods based on
the underlying distribution of the data.
Graphical methods including scatter plots and box-
plots will be used to visualize possible correlations be-
tween continuous parameters and differences between
intervention groups.
All analyses will employ SAS Version 9.1.
Interim analyses and stopping rules
No formal interim analysis is planned. Patients whose
study therapy will be stopped due to toxicity will be con-
sidered treatment failures. In case of safety concerns, e.g.
toxic events CTCAE grade 3 or more in more than 5%of patients, the principal investigator has to decide on
early study termination.
Data handling, storage and archiving of data
According to the §13 of the German GCP-Regulation all
important trial documents will be achieved for at least
10 years after the trial termination.
According to the §28c of the German X-ray Regulation
(RöV) and the §87 of the German Radiation Protection
Regulation (StrlSchV) the informed consent forms includ-
ing patients consent for trial participation, application of
irradiation and data transmission to the competent au-
thority will be achieved for at least 30 years after the trial
termination.
The Clinical Trials Center of the Department of Radi-
ation Oncology will be responsible for archiving all rele-
vant data.
Good clinical practice (GCP)
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation, and documentation of this
trial, are designed to ensure that all persons involved in
the trial follow the guidelines of Good Clinical Practice
(GCP) and the ethical principles described in the applic-
able version of the Declaration of Helsinki (2008 Version
of the Declaration of Helsinki, adopted at the 59th
WMA General Assembly, Seoul, October 2008), as well
as in accordance with the “Berufsordnung für Ärztinnen
und Ärzte” in the most recent version. The trial will be
carried out in adherence to local legal and regulatory
requirements.
Ethics, informed consent and legal aspects
A positive Ethics Vote was obtained from the independ-
ent Ethics Committee of the Medical Faculty of the
University of Heidelberg, Germany (S-542/2010) and the
local ethics committee of every participating site. The
SUPPORT trial is registered at http://www.clinicaltrials.
gov website, number NCT01693159.
Participation of a patient in this study is voluntary. Be-
fore being admitted to the clinical trial, the subject must
consent to participate after the nature, scope, and pos-
sible consequences of the clinical trial have been ex-
plained in a form understandable to him or her. The
subject must give written informed consent for study
participation. A subject may voluntarily discontinue par-
ticipation in this study at any time at their own request.
Before study entry, patients will be informed by the writ-
ten information brochure as well as orally about the
planned procedures within this study, especially about
potential benefits or potential risks. Informed consent
will be documented by the patient's signature on the in-
formed consent form.
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quest, the reason should be asked for as extensively as
possible and should be documented. All data acquired
within this study will be allowed for further evaluation
and inclusion into the final analysis due to written in-
formed consent and data privacy statement.
The data obtained in the course of the trial will
be treated pursuant to the Federal Data Protection
Law (Bundesdatenschutz- bzw. Landesdatenschutz-
gesetz, BDSG, LDSG).Discussion
EGFR inhibitors such as cetuximab are associated with a
unique group of class-specific cutaneous toxicities. Rha-
gades are one of the most painful and most dreaded
complications from EGFR inhibitor therapy Currently,
neither a scoring system for cetuximab-induced rhagades
for diagnostics nor a standard of care for the treatment
of the rhagades is established. Prevention and manage-
ment of EGFR-inhibitor-related rhagades, however, is
critical to maintain patients’ health-related quality of life
and dose intensity of antineoplastic regimens as the pain,
the discomfort and the reduced QoL caused by the rha-
gades can reduce compliance with anti-EGFR therapy.
For this reason, exact diagnosis and appropriate treat-
ment are very important. The SUPPORT trial is the first
randomized, controlled clinical trial evaluating a new
treatment option for painful cetuximab-induced rha-
gades. The main goal of this study is to show a superior-
ity of ECA compared to common standard treatments
for patients with LASCCHN developing painful rhagades
during combined radioimmunotherapy with the mono-
clonal EGFR-antibody cetuximab. Since there is no scor-
ing system for rhagades described elsewhere, the new
SUPO score will be prospectively assessed in terms of
clinical usefulness for the classification of EGFR inhibi-
tor induced rhagades. An effective management of the
painful rhagades is essential to assure a better quality of life
for the patients, to allow a better adherence to cancer
therapy and to avoid interruptions or even discontinuation
of antineoplastic treatment associated with poor outcome.
The results of the SUPPORT trial may help to define an
evidence-based treatment approach for EGFR-inhibitor in-
duced rhagades in the near future.Abbreviations
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